

# DxPx US 2023 Startup City Exhibitors

## Table of Contents

<b><u>DXPX US 2023 STARTUP CITY EXHIBITORS .....</u></b>	<b><u>1</u></b>
DERMAGNOSTIX .....	2
EPIGENDX .....	3
FLUIDAI MEDICAL .....	3
GATHER LABS .....	4
GENOMTEC.....	4
HUMMINGBIRD DIAGNOSTICS .....	5
INNOTECH PRECISION MEDICINE.....	5
ISCHEMIA CARE .....	6
IXENSOR CO. ....	6
LUMABS BV.....	6
NBCL.....	7
ONCOBIT.....	7
PACE DIAGNOSTICS.....	8
PHOENIX DX .....	8
PROLIGHT.....	9
SCIOMICS .....	9
BACTEROMIC.....	10
DYNAMIC BIOSENSORS .....	10
WINDYCITYSDR .....	11

Dermagnostix

Sarah Dion - **Chief Strategy Officer (CSO)**

[S.dion@dermagnostix.com](mailto:S.dion@dermagnostix.com)

<https://dermagnostix.com/>



At Dermagnostix, we develop groundbreaking diagnostics for dermatology to advance clinical practice and improve patients' lives. Our solution? Groundbreaking translational research meets cutting-edge technology: Dermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX, Dermagnostix launches the first in-class molecular test for differential diagnosis of psoriasis and eczema. Get diagnostic support for hard-to-tackle skin diseases using our simple and fast system: Sample in – Answer out.

EpigenDx

**Jose Estrada** - Senior Director of Marketing

[jestrada@epigendx.com](mailto:jestrada@epigendx.com)

<https://epigendx.com/>



EpigenDx was incorporated in 2006 as a genomic and epigenomic research company specializing in disease biomarker discovery, validation and molecular diagnosis, with an unmatched expertise in the field of DNA methylation analysis. EpigenDx provides superior products and laboratory services for scientific researchers from academic, government and industrial communities from all over the world. Our commitment to quality reflects our desire and dedication to provide the best products and services to our customers. EpigenDx has extensive knowledge and expertise in Pyrosequencing, bisulfite sequencing, and various epigenomic research analysis techniques and methods stemming from our years of experience in the industry.

FluidAI Medical

**Amr Abdelgawad** - COO & Co-founder

[rtjandra@fluidai.md](mailto:rtjandra@fluidai.md)

<https://fluidai.md/>



Real-Time Monitoring for Anastomotic Leaks with Origin, by FluidAI. Early data shows the potential of FluidAI's Origin real-time monitoring solution to detect leaks an average of 1.6 days post operatively<sup>1</sup>— which may:

- Accelerate Intervention & Improve Recovery
- Reduce Length of Stay
- Reduce Readmissions

Gather Labs

Rachael McCrary - Founder and CEO

[rm@gatherlabs.com](mailto:rm@gatherlabs.com)

<https://gatherlabs.com/>



**GATHER LABS**

Gather Labs, a Beverly Hills-based, women-founded lab, excels in providing rapid, accurate diagnoses for various health conditions, including COVID-19, hormonal imbalances, and autoimmune disorders. Our unique process guarantees results delivered within 24 hours with superior concierge service, all backed by our High Complexity CLIA License. At DxPx, we aim to engage with industry leaders, potential partners, and investors, sharing our vision to revolutionize diagnostic testing.

Genomtec

Michal Wachowski - Chief Financial Officer

[m.wachowski@genomtec.com](mailto:m.wachowski@genomtec.com)

<https://genomtec.com/en/>

**GENOMTEC** 

Genomtec is a Molecular Diagnostics venture committed to introducing a fast mobile point of care molecular testing platform using our proprietary method of detection - Streamlined Nucleic Acid Amplification Technology (SNAAT®) that utilizes isothermal chemistry. Our platform is design to test various infectious disease assays and companion diagnostics tests in field of oncology. Fast, cheap and reliable diagnostics is the dream of many doctors, veterinarians, parents, patients and scientists. It is also a condition for humanity to be able to effectively fight such threats as growing antibiotic resistance, increase in the number of cancer cases, or complications due to bacterial and viral infections. Genomtec combines confidence in molecular diagnostics with radical simplicity and cost reduction. The company is currently looking for strategic partners who share a similar interest.

Hummingbird Diagnostics

Jochen Kohlhaas

[jkohlhaas@hb-dx.com](mailto:jkohlhaas@hb-dx.com)

<https://www.hummingbird-diagnostics.com/>



Hummingbird Diagnostics extracts deep insights into disease through the integrated analysis of both tumor and immune system derived small RNA biomarkers from whole blood. This dual interrogation of signal from disease and the host response to disease enables a highly sensitive, robust, and AI powered platform that will revolutionize how we diagnose, treat, and manage cancer and other diseases. Hummingbirds' achievements have been showcased in prestigious peer-reviewed publications, documenting unparalleled performance in the early detection of cancer and guiding precision treatment strategies.

InnoTech Precision Medicine

Roya Khosravifar – President and CEO

[roya@innotechprecisionmed.com](mailto:roya@innotechprecisionmed.com)

<https://innotechprecisionmed.com/>



Our mission is to save lives by developing and commercializing the Next Generation of Diagnostics for the simultaneous multiomics detection of biomarkers in a single test with unmatched performance and ease of use. Our approach is based on the understanding that the detection of complex diseases requires the determination of a clear view of genomics, proteomics, metabolomic, and microbiomes. Our patented technology is based on the multi-modal and simultaneous detection of multiple classes of disease biomarkers in one test to provide accurate and early detection of diseases.

Ischemia Care

Jeff June - CEO / Board Member/ Founder

[jeff.june@iscdx.com](mailto:jeff.june@iscdx.com)

<https://www.ischemiacare.com/>

**ISCHEMIA CARE**

Ischemic Stroke Lab - We take the mystery out of cryptogenic strokes.™ ISCDx testing is easy and cost effective. Simply contact Ischemic Stroke Lab and we'll work with your clinical team, lab, administration, and supply chain to make our test available at your facility. It's as simple as collecting a sample, sending to our CLIA laboratory, and receiving results, just as your hospital does with any other send-out test.

iXensor Co.

Liao Patrick – VP of Marketing & PR

[patrickliao@ixensor.com](mailto:patrickliao@ixensor.com)

[https://www.ixensor.com/ixensor\\_web/](https://www.ixensor.com/ixensor_web/)

**iXensor.**

iXensor, the pioneer of mobile health, revolutionizes healthcare by transforming smartphones into advanced lab-grade medical diagnostics. With a remarkable milestone in 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System, the world's first smartphone camera-based blood test to receive US FDA approval. Building upon its innovative PixoTech® platform, iXensor has expanded its horizons into diverse areas, encompassing self-testing and point-of-care solutions across women's health, diabetes, cardiovascular health, and infectious diseases. In addition to its own brand products, iXensor actively engages in technology licensing, co-developments, and Contract Development and Manufacturing Services to drive the growth of connected healthcare solutions.

LUMABS BV

Antonio Soares - CEO

[a.soares@lumabs.com](mailto:a.soares@lumabs.com)

<https://lumabs.com/>



**LUMABS BV** develops **Bioluminescence** sensors that allow low-picomolar detection of diverse protein biomarkers, anti-drug antibodies, therapeutic antibodies, viral spike protein and anti-viral antibodies in immunoassays. Our validated Next-Gen bioluminescence “mix-and-measure” homogenous immunoassay **platform** allows for highly sensitive and one-step biomolecule quantification directly in <1ul of complex human samples. We currently look to expand the breadth of antibodies for which we have developed patented Lumabs/RAPPID sensors through co-development. Move your immunoassays from a Heterogeneous format to a Homogeneous one - and gain a competitive edge in the marketplace.

NBCL

Rob Lips - Business development

[rob@nbcl.nl](mailto:rob@nbcl.nl)

<https://www.nbcl.nl/>

The logo for NBCL, consisting of the lowercase letters 'nbcl' in a bold, red, sans-serif font.

NBCL (Novel Biomarkers Catalyst Lab) was founded in 2012 and is located at our offices and laboratories at Kerkenbos in Nijmegen the Netherlands. NBCL has an experienced immunoassay development team and works on the development of new immunoassays on the NBCL platform.

NBCL has an assay development laboratory and can perform small scale immunoassay production. NBCL is dedicated to the development and commercialisation of immunoassays that are or become important diagnostic tools in clinical management.

Oncobit

Claudia Scheckel – CEO

[claudia.scheckel@oncobit.com](mailto:claudia.scheckel@oncobit.com)

<https://oncobit.com/en>

The logo for Oncobit, consisting of the lowercase letters 'oncobit' in a bold, blue, sans-serif font.

Oncobit: Enabling personalized cancer care

Oncobit is a MedTech Spinoff from the University Hospital of Zurich. We apply a unique combination of technical know-how, proprietary software and close clinical collaborations, to develop more sensitive and more precise cancer diagnostic and monitoring solutions to find the best cancer treatment for each patient. We are ISO 13485 certified and have built a portfolio of three tests for one of which we already have regulatory approval in Europe and filed a patent. While our initial focus is on melanoma, our data analysis platform not only enables us to provide robust and interpretable results but also to quickly scale to other cancer types. At DxPx, we are looking for investors as well industry partners to collaborate on the development of (companion) diagnostics.

PACE Diagnostics

Hiep-Hoa Nguyen – President

[hiephoa@pacediagnostics.com](mailto:hiephoa@pacediagnostics.com)

<https://pacediagnostics.com/>



Pace Diagnostics is an emerging biotechnology company focused on the research, development, licensing, manufacturing and marketing of cutting-edge diagnostics. Formed on the culmination of decades of basic and applied research, supported by grants and contracts from the US Federal Government.

Phoenix Dx

George Goh – CEO

[george.goh@phoenixdx.co.uk](mailto:george.goh@phoenixdx.co.uk)

<https://phoenixdx.co.uk/>



**PHOENIX DX**  
Rapid Diagnostic Technologies

At Phoenix DX we specialise in medical technology and diagnostics, and have a wealth of experience in delivering an exceptional service for testing providers, laboratory professionals, healthcare professionals and clinical setting managers around the world. Phoenix DX are the UK-based creators of Molerumi, a device for performing hand-held PCR tests. Molerumi is a quick and easy way to do PCR tests for Covid-19, providing you with fast and accurate results for more efficiency in your workplace. One of the first devices of its kind, it offers incredible performance at an affordable price, allowing clients in healthcare settings to manage workplace risk and infections rates more easily.



Prolight

Ulf Bladin, CEO

[ub@prolightdiagnostics.se](mailto:ub@prolightdiagnostics.se)

<https://prolightdx.com/>

# PROLIGHT

Diagnostics you can count on

Prolight Diagnostics is developing the Psyros™ digital immunoassay which promises to be a revolutionary diagnostic platform bringing unprecedented sensitivity and accuracy to point of care testing. Using a unique proprietary method of single molecule counting, reduced background dramatically increasing detection limits. The portable instrument and simple disposable cartridge design enables cost-effective manufacturing and enables testing directly on capillary whole blood, providing results in minutes. The initial high-sensitive troponin detection assay showcases the technology's exceptional sensitivity and simplicity of use. We aim to develop partnership to expand to a wide range of potential future applications, including cardiology, neurological pathologies (dementia, traumatic brain injury etc.), immune system dysfunction (sepsis, autoimmune disease) and virus detection, including Covid and more.

Sciomics

Christoph Schroeder – CEO

[schroeder@sciomics.de](mailto:schroeder@sciomics.de)

<https://www.sciomics.de/>



At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform. In addition, we offer services based on our scioDiscover profiling platform and R&D collaborations for the discovery and validation of novel biomarkers, for drug target screening, the characterization of disease models, and for the analysis of pathway activity as well as mode-of-action analyses. What sets us apart is our team of scientific experts that takes pride in custom-tailoring every project and consulting clients throughout the project. Our full service ranges from discussing experimental designs to in-depth data analysis and a comprehensive study report. Fast and cost-efficient, Sciomics' powerful high-content, high-throughput antibody array platform delivers reliable results that can be easily translated into validation or clinical assays, thereby generating value and opening new avenues for biomarker discovery as well as preclinical drug discovery & development programs.

BacterOMIC

Mikołaj Mioduszewski - Corporate Development

[mikolaj.mioduszewski@scopefluidics.com](mailto:mikolaj.mioduszewski@scopefluidics.com)

<https://bacteromic.com/>



BacterOMIC aims to revolutionize AST by offering complete, quantitative evaluation of all clinically relevant antibiotics in a single test and a capacity to test synergistic combinations of antibiotics for multidrug-resistant infections. System combines cutting-edge microfluidics, detection, data analysis, and automation with the aim to deliver unprecedented information content, throughput, and ease of use. BacterOMIC is developed by Scope Fluidics – first MedTech Venture Studio in CEE.

We are open to discuss our technology with industry professionals and explore collaboration opportunities

Dynamic Biosensors

Ulrich Rant - CEO

[ulrich.rant@dynamic-biosensors.com](mailto:ulrich.rant@dynamic-biosensors.com)

<https://www.dynamic-biosensors.com/>

**dynamic**  
BIOSENSORS

Dynamic Biosensors provides instruments and consumables for the advanced analysis of biomolecular interactions on biochips and single cells, which enable breakthroughs in drug discovery, life science research, and cell & gene therapies.

Dynamic Biosensors commercializes **switchSENSE<sup>®</sup>** and **Real-Time Interaction Cytometry (RT-IC)** technologies. **switchSENSE<sup>®</sup>** is a unique platform technology for the analysis of molecule-molecule interactions. **RT-IC** is a groundbreaking technology enabling the real-time measurement of molecules binding to membrane targets on cells.

The company is headquartered in Munich, Germany, and runs offices in the United States, the United Kingdom, France, Japan, and Singapore.

WindyCitySDR

Martin O'Shield - Founder/CEO

[Martin@windycitysd.com](mailto:Martin@windycitysd.com)

<http://www.windycitysd.com/>



WindyCitySDR, teaming up with Drexel University's Theoretical & Applied Mechanics Group, manufactures wideband software defined radios which allows for creating complete wireless communications systems entirely in software unlike our existing "Hardware Radios" such as your TV, AM/FM radios, and/or Magnetic Resonance Imaging machine you can't "Software Upgrade" to the "Next New Thing". Example: A "hardware radio", such as a 4G LTE Smartphone, can't be "Software Upgraded" to a 5G Smartphone but with a "software defined radio", you can easily switch between 4G & 5G, just by changing your software.